uniQure N.V. (QURE) is focused on its gene therapy AMT-130, aimed at treating Huntington’s disease, a condition with no existing disease-modifying treatments. Recent FDA feedback from a Type B meeting has improved investor sentiment, indicating that a targeted biologics license application could be submitted in the third quarter of 2026, with three-year data from the ongoing phase I/II study potentially serving as the basis for accelerated approval.
As of the end of Q1 2026, uniQure reported $586.6 million in cash and equivalents, providing operational funding into the second half of 2029. The company’s strategic focus on AMT-130 is crucial, given earlier regulatory feedback questioning the adequacy of external control data for proving effectiveness. Additionally, the company is also advancing other therapies, including AMT-260 for epilepsy and AMT-191 for Fabry disease, though these represent less immediate value compared to AMT-130.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
